The genesis of colorectal and pancreatic cancer involves the interaction of environmental and heritable causes. Key to discoveries in diagnosis and treatment of these malignancies is the understanding of these factors by investigation of well-characterized and available patient data and specimens. The goal of CORE 3 is to provided SPORE and other investigators with these materials to support the research of familial, environmental and molecular genetic factors in both colorectal and pancreatic cancer. With this regard, a registry and clinical study of patients with hereditary colorectal cancer and polyposis syndromes were founded at the Johns Hopkins Hospital in 1973. In 1982, the Bowel Tumor Working Group was formed to study the pathobiology and molecular genetics of colorectal tumors. In 1991 the CORE 3 was formed. The CORE is maintained in computerized Access and Progeny data bases and includes: 1) families with a history of familial aggregation of colorectal cancer, early onset colorectal cancer and polyposis syndromes and 2) family histories and food frequency questionnaires on patients evaluated for colorectal neoplasm. The CORE was expanded in 1996 to include similar data on pancreatic cancer patients.
The specific aims of CORE 3 are: 1. To collect family history, medical history, pathological records, environmental/exposure data and dietary date from at risk and affected individuals with colorectal and pancreatic neoplasm and associated syndromes. 2. To procure specimens including blood and stool in at risk and affected individuals with colorectal and pancreatic neoplasm and associated syndromes.

Public Health Relevance

The importance of the knowledge gained by the data accumulated by this CORE is significant and multifactorial. Benefits from this knowledge might include risk markers necessary for the initiation of preventive surveillance strategies, diagnostic markers essential to the appropriate medical and surgical treatment of these tumors, and therapeutic targets needed for the development of medical therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA062924-20
Application #
8559521
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
20
Fiscal Year
2013
Total Cost
$121,058
Indirect Cost
$46,154
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Al Efishat, Mohammad A; Attiyeh, Marc A; Eaton, Anne A et al. (2018) Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg 268:340-347
Cruz-Correa, Marcia; Hylind, Linda M; Marrero, Jessica Hernandez et al. (2018) Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. Gastroenterology 155:668-673
Christmas, Brian J; Rafie, Christine I; Hopkins, Alexander C et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561-1577
Blair, Alex B; Murphy, Adrian (2018) Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer 42:49-58
Raman, Aadhithya; Lennon, Anne Marie (2018) Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas. Visc Med 34:178-181
Noë, Michaël; Pea, Antonio; Luchini, Claudio et al. (2018) Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Mod Pathol 31:1532-1538
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Shumar, Stephanie A; Kerr, Evan W; Geldenhuys, Werner J et al. (2018) Nudt19 is a renal CoA diphosphohydrolase with biochemical and regulatory properties that are distinct from the hepatic Nudt7 isoform. J Biol Chem 293:4134-4148
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118

Showing the most recent 10 out of 883 publications